Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2000 Jun 19;191(12):2031–2038. doi: 10.1084/jem.191.12.2031

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2000 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Retrovirus-mediated expression of Bcl-X_L in DO.11 WT and DO.11 CD28^−/− primary T lymphocytes. T cells were activated in vitro with OVA peptide and APCs and infected on day 1 with retrovirus encoding either GFP alone (control virus) or Bcl-X_L and GFP (Bcl-X_L virus). (A) Cells were collected and stained at day 3 after viral infection with antibodies to CD4 and the DO.11 TCR (KJ1-26) and analyzed for GFP expression in CD4⁺KJ1-26⁺ cells by flow cytometry. The number beside the FACS^® plot represents the percentage of CD4⁺KJ1-26⁺ T cells. FSC, forward scatter. (B) Cells infected with retrovirus containing GFP alone or GFP/Bcl-X_L as in A were cultured for an additional 4 d in the presence of APCs and OVA peptide, collected, lysed, and analyzed by Western blotting with a polyclonal antiserum specific for Bcl-X_L/S protein.

HHS Vulnerability Disclosure